Prime Medicine, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRME research report →
Companywww.primemedicine.com
Prime Medicine, Inc. , a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
- CEO
- Allan Reine
- IPO
- 2022
- Employees
- 214
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $512.00M
- P/E
- -2.53
- P/S
- 126.92
- P/B
- 6.55
- EV/EBITDA
- -2.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1082.70%
- Op Margin
- -5121.76%
- Net Margin
- -4917.55%
- ROE
- -188.82%
- ROIC
- -77.39%
Growth & Income
- Revenue
- $4.63M · 55.28%
- Net Income
- $-201,142,000 · -2.69%
- EPS
- $-1.35 · 18.26%
- Op Income
- $-208,350,000
- FCF YoY
- -28.38%
Performance & Tape
- 52W High
- $6.94
- 52W Low
- $1.11
- 50D MA
- $3.51
- 200D MA
- $4.00
- Beta
- 2.36
- Avg Volume
- 2.55M
Get TickerSpark's AI analysis on PRME
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Makhni Svetlana Ni | other | 800,000 |
| Apr 16, 26 | Makhni Svetlana Ni | other | 0 |
| Feb 26, 26 | Reine Allan | other | 1,300,000 |
| Feb 23, 26 | LEE ANN L. | other | 375,000 |
| Feb 23, 26 | Alenson Carman | other | 140,000 |
| Aug 1, 25 | LEE ANN L. | other | 180,995 |
| Aug 1, 25 | LEE ANN L. | sell | 180,995 |
| Aug 1, 25 | LEE ANN L. | sell | 180,995 |
| Aug 1, 25 | Schenkein David P | other | 45,000 |
| Aug 1, 25 | Schenkein David P | other | 39,062 |
Our PRME Coverage
We haven't published any research on PRME yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRME Report →